Free Trial

Verrica Pharmaceuticals (VRCA) Competitors

Verrica Pharmaceuticals logo
$3.85 -0.10 (-2.53%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$3.89 +0.04 (+1.04%)
As of 10/24/2025 07:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

VRCA vs. FBRX, ARTV, CRDF, ACOG, CTOR, TCRX, BTMD, TVGN, ANIX, and CLYM

Should you be buying Verrica Pharmaceuticals stock or one of its competitors? The main competitors of Verrica Pharmaceuticals include Forte Biosciences (FBRX), Artiva Biotherapeutics (ARTV), Cardiff Oncology (CRDF), Alpha Cognition (ACOG), Citius Oncology (CTOR), TScan Therapeutics (TCRX), biote (BTMD), Tevogen Bio (TVGN), Anixa Biosciences (ANIX), and Climb Bio (CLYM). These companies are all part of the "pharmaceutical products" industry.

Verrica Pharmaceuticals vs. Its Competitors

Forte Biosciences (NASDAQ:FBRX) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk.

77.6% of Forte Biosciences shares are held by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are held by institutional investors. 5.9% of Forte Biosciences shares are held by insiders. Comparatively, 54.0% of Verrica Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Forte Biosciences has higher earnings, but lower revenue than Verrica Pharmaceuticals. Forte Biosciences is trading at a lower price-to-earnings ratio than Verrica Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Forte BiosciencesN/AN/A-$35.48M-$16.29-0.74
Verrica Pharmaceuticals$7.57M4.81-$76.58M-$8.28-0.46

Forte Biosciences currently has a consensus target price of $68.00, suggesting a potential upside of 461.52%. Verrica Pharmaceuticals has a consensus target price of $20.00, suggesting a potential upside of 419.48%. Given Forte Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Forte Biosciences is more favorable than Verrica Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Forte Biosciences
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Verrica Pharmaceuticals
1 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.75

In the previous week, Verrica Pharmaceuticals had 6 more articles in the media than Forte Biosciences. MarketBeat recorded 8 mentions for Verrica Pharmaceuticals and 2 mentions for Forte Biosciences. Forte Biosciences' average media sentiment score of 1.48 beat Verrica Pharmaceuticals' score of 1.09 indicating that Forte Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Forte Biosciences
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Verrica Pharmaceuticals
3 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Verrica Pharmaceuticals' return on equity of 0.00% beat Forte Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Forte BiosciencesN/A -85.38% -72.34%
Verrica Pharmaceuticals N/A N/A -115.48%

Forte Biosciences has a beta of 3.03, indicating that its share price is 203% more volatile than the S&P 500. Comparatively, Verrica Pharmaceuticals has a beta of 1.71, indicating that its share price is 71% more volatile than the S&P 500.

Summary

Forte Biosciences beats Verrica Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Get Verrica Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for VRCA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VRCA vs. The Competition

MetricVerrica PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$37.31M$2.97B$6.23B$10.66B
Dividend YieldN/A57.75%5.71%4.82%
P/E Ratio-0.4625.2430.2030.21
Price / Sales4.81782.34590.34132.63
Price / CashN/A168.3237.0161.44
Price / Book-3.605.6512.046.60
Net Income-$76.58M$33.06M$3.32B$276.82M
7 Day Performance-7.23%3.15%1.89%2.58%
1 Month Performance-5.87%8.13%7.68%3.76%
1 Year Performance-74.50%-2.49%56.01%33.84%

Verrica Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VRCA
Verrica Pharmaceuticals
3.9201 of 5 stars
$3.85
-2.5%
$20.00
+419.5%
-74.3%$37.31M$7.57M-0.4640Positive News
Analyst Forecast
FBRX
Forte Biosciences
3.0093 of 5 stars
$12.19
+0.9%
$68.00
+457.8%
+158.2%$150.19MN/A-0.755News Coverage
Short Interest ↑
ARTV
Artiva Biotherapeutics
3.9105 of 5 stars
$4.91
-18.3%
$18.25
+271.7%
-46.8%$146.80M$250K0.0081Gap Up
CRDF
Cardiff Oncology
2.3437 of 5 stars
$2.28
+4.1%
$10.63
+366.0%
-18.3%$145.69M$680K-2.6220News Coverage
Analyst Forecast
Gap Up
ACOG
Alpha Cognition
2.6548 of 5 stars
$7.13
+4.9%
$18.00
+152.5%
N/A$142.13M$4.59M-4.46N/AShort Interest ↑
Analyst Revision
CTOR
Citius Oncology
2.0684 of 5 stars
$1.79
+5.3%
$6.00
+235.2%
+39.8%$141.97MN/A0.00N/ANews Coverage
Analyst Forecast
Gap Up
High Trading Volume
TCRX
TScan Therapeutics
2.8589 of 5 stars
$2.52
+1.6%
$7.80
+209.5%
-53.5%$140.74M$6.96M-2.31100
BTMD
biote
2.1589 of 5 stars
$2.93
+3.2%
$6.00
+104.8%
-42.4%$140.41M$197.19M3.26194News Coverage
Analyst Upgrade
TVGN
Tevogen Bio
2.6797 of 5 stars
$0.70
0.0%
$10.00
+1,325.9%
-74.0%$138.01MN/A-3.693News Coverage
Analyst Forecast
ANIX
Anixa Biosciences
3.2117 of 5 stars
$4.29
+4.6%
$9.00
+109.8%
+31.4%$134.96M$210K-12.265Gap Up
CLYM
Climb Bio
3.6405 of 5 stars
$2.32
+20.2%
$9.20
+296.6%
N/A$130.79MN/A-3.319Analyst Forecast
Gap Up

Related Companies and Tools


This page (NASDAQ:VRCA) was last updated on 10/25/2025 by MarketBeat.com Staff
From Our Partners